Biotek-snakken — September 2024
-
FDA Approves Zevra Therapeutics' MIPLYFFA For Treatment Of Niemann-Pick Disease Type C https://proinvestor.com/investornyt/1216783/fda-approves-zevra-therapeutics-miplyffa-for-treatment-of-niemann-pick-disease-type-c
-
FDA greenlights Sanofi's Sarclisa in frontline multiple myeloma https://firstwordpharma.com/story/5897967
-
Sanofi gears up to seek approval of BTK inhibitor tolebrutinib in MS https://firstwordpharma.com/story/5897608
-
Genovis Launches FabRICATOR
Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
Genovis AB, a leading provider of innovative enzyme technologies, announce the launch of
News Powered by Cision (news.cision.com)
-
Travere Therapeutics Pauses Enrollment In Phase 3 Study Of Pegtibatinase For Manufacturing Scale-Up https://proinvestor.com/investornyt/1219391/travere-therapeutics-pauses-enrollment-in-phase-3-study-of-pegtibatinase-for-manufacturing-scale-up
-
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up https://proinvestor.com/investornyt/1219387/biomea-fusion-fda-lifts-clinical-hold-on-bmf-219-for-type-1-and-type-2-diabetes-trials-stock-up
-
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment https://proinvestor.com/investornyt/1219377/bristol-myers-squibbs-cobenfy-gains-fda-approval-for-adult-schizophrenia-treatment
-
Evaxion significantly expands vaccine development collaboration with MSD https://investors.evaxion-biotech.com/news-releases/news-release-details/evaxion-significantly-expands-vaccine-development-collaboration
-
Evaxion sælger rettigheder til to vaccinekandidater for potentielt milliardbeløb
Det er partneren MSD, som køber retten til en vaccinekandidat mod gonoré og et ikke-offentliggjort infektionsmiddel. (Medwatch abonnement) https://medwatch.dk/Medicinal___Biotek/article17484915.ece?utm_campaign=MedWatch Topnyhed&utm_content=2024-09-26&utm_medium=email&utm_source=medwatch -
SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements https://proinvestor.com/investornyt/1219394/sec-announces-40-mln-settlement-with-cassava-sciences-over-misleading-alzheimers-trial-statements
-
AbbVie sets sights on clinical hat trick for Cerevel Parkinson's drug https://firstwordpharma.com/story/5899132
-
AstraZeneca scores wider US lung cancer label for Tagrisso https://firstwordpharma.com/story/5899045
-
FDA panel votes against PD-1s in gastric, oesophageal cancers with low biomarker expression https://firstwordpharma.com/story/5899318
-
Lundbeck vil forstå kronisk nervesygdom bedre med nyt studie https://proinvestor.com/investornyt/1219563/lundbeck-vil-forsta-kronisk-nervesygdom-bedre-med-nyt-studie
-
Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients https://proinvestor.com/investornyt/1220121/enliven-therapeutics-updates-positive-phase-1-data-for-elvn-001-in-chronic-myeloid-leukemia-patients
-
I
s Viking Therapeutics Stock a Buy? https://proinvestor.com/investornyt/1220185/is-viking-therapeutics-stock-a-buy
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind